Iodine-Ethanol Contrast Composition for Single-Injection Sclerotherapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing sclerotherapy procedures for treating venous malformations, arteriovenous malformations, and abdominal cystic diseases are cumbersome, require multiple injections, and pose risks due to the use of anhydrous ethanol, which is not visible under imaging and can leak, leading to increased side effects.

Innovation Solution

A pharmaceutical composition comprising an iodine contrast agent, ethanol, and water, formulated as a homogeneous solution with specific concentration ranges, allowing for a single injection that provides both imaging and treatment, reducing the complexity and risks associated with traditional methods.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If anhydrous ethanol is used as a sclerosing agent, then vascular embolization and cyst closure effects are achieved, but the agent is not visible under imaging and can leak, leading to increased side effects

Engineering Contradiction:

Improveimaging visibilityVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines the sclerosing agent (ethanol) with an iodine contrast agent into a single composite solution. This merging allows the solution to provide both therapeutic embolization effects and imaging visibility simultaneously, eliminating the need for separate injection steps and reducing the risk of leakage-related side effects.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a composite pharmaceutical composition by dissolving iodine contrast agent in ethanol. This composite material retains the vascular embolization properties of ethanol while gaining the radiopacity of iodine contrast agents, enabling dual functionality in a single agent.

Inventive Principle:

Principle #40Composite materials

2Productivity

If traditional sclerotherapy uses separate contrast agent and sclerosing agent injections, then imaging and treatment can be performed, but the procedure becomes cumbersome and time-consuming

Engineering Contradiction:

Improvetreatment efficiencyVSAvoidprocedure complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent merges the functions of contrast agent injection and sclerosing agent injection into a single injection step. The composite solution contains both imaging components and therapeutic components, allowing simultaneous diagnosis and treatment, thereby improving productivity and reducing procedural complexity.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The composite pharmaceutical composition serves multiple functions: it provides imaging contrast for visualization, delivers the sclerosing effect for embolization, and enables monitoring of treatment progression. This multi-functionality eliminates the need for separate agents and steps, streamlining the overall procedure.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Loss of time

If multiple injections are used for contrast and treatment, then imaging and therapy are achieved, but the treatment time and procedural complexity increase

Engineering Contradiction:

Improvetreatment timeVSAvoidoperational simplicity

Core Design Contradiction:

Loss of timeVSEase of operation

Solution Approach 1:

By combining contrast agent and sclerosing agent into a single injectable solution, the patent reduces the number of injection steps from two to one. This merging directly reduces treatment time and simplifies the operational process, making the procedure easier to perform while maintaining both diagnostic and therapeutic functions.

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition enables precise, single-step treatment with reduced side effects, improved imaging capabilities, and lower tissue damage, while maintaining effective vascular embolization and cyst closure.

Implementation Method 1

improved imaging capabilities

Methodology Applied

Scientific EffectX-ray absorption: Absorption (EM radiation)

Implementation Method 2

anhydrous ethanol or other sclerosing agents come into contact with the cyst wall, leading to coagulation and denaturation of the cyst wall cell proteins

Methodology Applied

Scientific EffectCoagulation: Coagulation

Implementation Method 3

coagulation and denaturation of the cyst wall cell proteins

Methodology Applied

Scientific EffectDenaturation:

Implementation Method 4

induces extensive intravascular thrombosis and fibrosis

Methodology Applied

Scientific EffectThrombosis: Coagulation

Implementation Method 5

formulated as a homogeneous solution with specific concentration ranges

Methodology Applied

Scientific EffectHomogeneous solution:

Data Source

PatentEP4729076A1Iodine contrast agent composition

Publication Date: 2026.04.22 CHENGDU BRILLIANT PHARMA CO LTD

Figure 1~2
Figure 3

AI summary

The present application discloses an iodine contrast agent composition comprising an iodine contrast agent, ethanol, and water, wherein based on the volume of the pharmaceutical composition, the content of the iodine contrast agent is 208 mg/mL to 624 mg/mL, and the content of the ethanol is 484 mg/mL to 677 mg/mL. This composition provides good vascular embolization and in vitro and in vivo imaging effects, which can meet the clinical requirements of image visualization. The solution is clear, homogeneous, stable, safe, and causes low irritation and has minimal impact on the tissues surrounding the lesion.